In this randomised control trial in people with MASLD without diabetes, LiverMultiScan monitored improvements in liver fat and liver disease activity following 12-week treatment with liraglutide, and the subsequent rebound after cessation. A low-calorie diet of similar duration achieved equivalent improvements.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?